Analysts Predict 11% Growth Potential for IWS Holdings
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Sep 22 2025
0mins
Should l Buy MRNA?
Source: NASDAQ.COM
ETF Analysis: The iShares Russell Mid-Cap Value ETF (IWS) has an implied analyst target price of $153.61, indicating a potential upside of 10.74% from its current trading price of $138.72.
Notable Holdings: Key underlying holdings with significant upside potential include Viking Therapeutics (VKTX), Moderna (MRNA), and Civitas Resources (CIVI), with expected target price increases of 251.09%, 65.65%, and 37.99%, respectively.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MRNA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MRNA
Wall Street analysts forecast MRNA stock price to fall
19 Analyst Rating
1 Buy
14 Hold
4 Sell
Hold
Current: 40.510
Low
17.00
Averages
29.36
High
63.00
Current: 40.510
Low
17.00
Averages
29.36
High
63.00
About MRNA
Moderna, Inc. is a biotechnology company. The Company is advancing a new class of medicines made of messenger ribonucleic acid (mRNA). It is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane or secreted proteins that have a therapeutic or preventive benefit with the potential to address a spectrum of diseases. The Company’s diverse development pipeline consists of 44 therapeutic and vaccine programs, 11 of which are in late-stage development. Its commercial products include Spikevax (its COVID vaccine) and mRESVIA (its respiratory syncytial virus (RSV) vaccine). Additionally, it has achieved four positive Phase III data readouts for its COVID vaccine (mRNA-1283), its RSV vaccine for high-risk adults aged 18 to 59 (mRNA-1345), its seasonal flu+COVID vaccine (mRNA-1083), and its seasonal flu vaccine (mRNA-1010).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
MODERNA STOCK PLUMMETS 11.5% FOLLOWING US FDA'S DECISION NOT TO EVALUATE COMPANY'S INFLUENZA VACCINE APPLICATION
Moderna's Stock Reaction: Moderna's shares dropped by 11.5% following the refusal of the U.S. Food and Drug Administration (FDA) to review the company's influenza vaccine application.
FDA's Decision Impact: The FDA's decision not to review the influenza vaccine application has raised concerns about the future of Moderna's vaccine development efforts.
See More
FDA Declines to Review Approval for Moderna's New Flu Vaccine - WSJ
- FDA Refusal: The FDA has declined to consider the approval of Moderna's new flu vaccine.
- Impact on Public Health: This decision may affect the availability of new flu vaccination options for the upcoming flu season.
See More
MODERNA: U.S. FOOD AND DRUG ADMINISTRATION ISSUES REFUSAL-TO-FILE LETTER FOR MRNA-1010 SEASONAL INFLUENZA VACCINE CANDIDATE
Regulatory Update: Moderna has received a refusal letter from the U.S. Food and Drug Administration regarding its investigational seasonal influenza vaccine, mRNA-1010.
Vaccine Details: The vaccine is designed to target multiple strains of the influenza virus, but the FDA's decision indicates concerns that need to be addressed before moving forward.
See More
Market Update: S&P 500 Declines and Upcoming CPI Data
- CPI Expectations: The consumer price index, set to be released at 8:30 a.m. ET on Friday, is expected to show a month-over-month increase of 0.3% and a year-over-year rise of 2.5%, which could significantly influence market sentiment and lead investors to reassess their risk appetite.
- Moderna Stock Fluctuations: Moderna's shares have surged 50% over the past three months, closing at $40.11 on Thursday, although this remains significantly lower than the pandemic peak of $497, indicating ongoing volatility in biotech stocks that investors are closely monitoring.
- Wendy's Stock Decline: Wendy's shares fell 7.7% on Thursday, down 55% from their 52-week high, highlighting the persistent pressures facing the fast-food industry, which may impact its future market performance.
- Retail Sector Dynamics: The Amplify Online Retail ETF dropped nearly 4% on Thursday, now down 19.5% from its September high, reflecting weakness in the retail market, especially after experiencing five consecutive weeks of declines, which could negatively affect overall consumer confidence.
See More
Stocks Reverse Early Gains as All Indexes Decline Over 1%.
- Market Performance: The market experienced fluctuations, starting positively but ultimately closing lower for all three major indexes.
- Investor Sentiment: There is a sense of confusion among investors due to the market's inconsistent behavior, often referred to as "head fakes."
See More
Market Focus on Inflation and Earnings Reports
- Inflation Data Release: The January Consumer Price Index (CPI) is set to be released on February 13, with economists expecting the headline CPI to remain at 0.3% while core CPI rises from 0.2% to 0.3%, potentially influencing the Fed's rate decisions.
- Moderna Earnings Outlook: Moderna is scheduled to report its fourth-quarter results on Friday, with analysts anticipating the company to reaffirm its sales growth outlook of about 10% for 2026, although questions about the durability of this outlook may affect investor confidence.
- Wendy's Sales Forecast: Wendy's is projecting a decline in same-store sales in the high single digits for Q4, primarily due to tougher comparisons from last year and promotional activities, which could pressure the company in the competitive fast-food market.
- Enbridge Financial Forecast: Enbridge expects its fourth-quarter EBIDA to remain flat year-over-year, keeping it near the upper end of its full-year guidance range, with investors keen on updates regarding cash flow growth in 2026 and the impact of currency dynamics on its outlook.
See More
MODERNA STOCK PLUMMETS 11.5% FOLLOWING US FDA'S DECISION NOT TO EVALUATE COMPANY'S INFLUENZA VACCINE APPLICATION
Moderna's Stock Reaction: Moderna's shares dropped by 11.5% following the refusal of the U.S. Food and Drug Administration (FDA) to review the company's influenza vaccine application.
FDA's Decision Impact: The FDA's decision not to review the influenza vaccine application has raised concerns about the future of Moderna's vaccine development efforts.
See More
FDA Declines to Review Approval for Moderna's New Flu Vaccine - WSJ
- FDA Refusal: The FDA has declined to consider the approval of Moderna's new flu vaccine.
- Impact on Public Health: This decision may affect the availability of new flu vaccination options for the upcoming flu season.
See More
MODERNA: U.S. FOOD AND DRUG ADMINISTRATION ISSUES REFUSAL-TO-FILE LETTER FOR MRNA-1010 SEASONAL INFLUENZA VACCINE CANDIDATE
Regulatory Update: Moderna has received a refusal letter from the U.S. Food and Drug Administration regarding its investigational seasonal influenza vaccine, mRNA-1010.
Vaccine Details: The vaccine is designed to target multiple strains of the influenza virus, but the FDA's decision indicates concerns that need to be addressed before moving forward.
See More
Market Update: S&P 500 Declines and Upcoming CPI Data
- CPI Expectations: The consumer price index, set to be released at 8:30 a.m. ET on Friday, is expected to show a month-over-month increase of 0.3% and a year-over-year rise of 2.5%, which could significantly influence market sentiment and lead investors to reassess their risk appetite.
- Moderna Stock Fluctuations: Moderna's shares have surged 50% over the past three months, closing at $40.11 on Thursday, although this remains significantly lower than the pandemic peak of $497, indicating ongoing volatility in biotech stocks that investors are closely monitoring.
- Wendy's Stock Decline: Wendy's shares fell 7.7% on Thursday, down 55% from their 52-week high, highlighting the persistent pressures facing the fast-food industry, which may impact its future market performance.
- Retail Sector Dynamics: The Amplify Online Retail ETF dropped nearly 4% on Thursday, now down 19.5% from its September high, reflecting weakness in the retail market, especially after experiencing five consecutive weeks of declines, which could negatively affect overall consumer confidence.
See More
Stocks Reverse Early Gains as All Indexes Decline Over 1%.
- Market Performance: The market experienced fluctuations, starting positively but ultimately closing lower for all three major indexes.
- Investor Sentiment: There is a sense of confusion among investors due to the market's inconsistent behavior, often referred to as "head fakes."
See More
Market Focus on Inflation and Earnings Reports
- Inflation Data Release: The January Consumer Price Index (CPI) is set to be released on February 13, with economists expecting the headline CPI to remain at 0.3% while core CPI rises from 0.2% to 0.3%, potentially influencing the Fed's rate decisions.
- Moderna Earnings Outlook: Moderna is scheduled to report its fourth-quarter results on Friday, with analysts anticipating the company to reaffirm its sales growth outlook of about 10% for 2026, although questions about the durability of this outlook may affect investor confidence.
- Wendy's Sales Forecast: Wendy's is projecting a decline in same-store sales in the high single digits for Q4, primarily due to tougher comparisons from last year and promotional activities, which could pressure the company in the competitive fast-food market.
- Enbridge Financial Forecast: Enbridge expects its fourth-quarter EBIDA to remain flat year-over-year, keeping it near the upper end of its full-year guidance range, with investors keen on updates regarding cash flow growth in 2026 and the impact of currency dynamics on its outlook.
See More
